The global gene therapy market for central nervous system (CNS) disorders is set for remarkable growth, with an expected valuation of US$ 8.2 billion in 2023 and projected to soar to approximately US$ 113.04 billion by 2033. This growth represents a staggering compound annual growth rate (CAGR) of 30% during the forecast period from 2023 to 2033. The market exhibited significant expansion in the historical period from 2018 to 2022, recording a CAGR of 19%.
The surge in the gene therapy market for CNS disorders can be attributed to rapid advancements in genetic engineering technologies, increasing prevalence of neurological diseases, and a growing pipeline of innovative gene-based therapies. As research continues to unveil the complexities of CNS disorders, gene therapy is emerging as a promising approach to address previously untreatable conditions, offering new hope for patients suffering from diseases such as Alzheimer’s, Parkinson’s, and Huntington’s.
North America is currently leading the market, driven by substantial investment in biotech research and development, a favorable regulatory environment, and strong academic collaborations. The Asia-Pacific region is also anticipated to witness significant growth due to increasing healthcare expenditures, rising awareness of gene therapies, and improved access to cutting-edge medical technologies.
As the gene therapy landscape continues to evolve, industry players are expected to focus on expanding their research efforts, forging strategic partnerships, and enhancing delivery mechanisms to optimize therapeutic efficacy. The future of the gene therapy market for CNS disorders looks bright, offering transformative solutions that could reshape the treatment paradigm for neurological diseases.
Which are Some Prominent Drivers of Gene Therapy in the CNS Disorder Market?
Growing advancements in diagnostic and treatment options to push the market growth
The global gene therapy in CNS disorder market is primarily driven by an increased prevalence of CNS disorders such as, such as Parkinson’s disease, Alzheimer’s disease, and ALS, which is on the rise, which is driving the demand for effective treatments.
Up to 1 billion people, nearly one in six of the world’s population, suffer from neurological disorders, from Alzheimer and Parkinson disease, strokes, multiple sclerosis and epilepsy to migraine, brain injuries and neuroinfections, with some 6.8 million dying of the maladies each year, according to a new United Nations report.
There have been significant advancements in gene therapy technology, including the development of viral vectors that can deliver therapeutic genes to the brain more efficiently and safely. Additionally, the growth of the Gene Therapy in CNS Disorder market is owed to ongoing research and development, which is leading to an increased potential for new and improved treatment options to become available for patients with CNS disorders. There is a growing investment in research and development of gene therapy for CNS disorders, with many biotech and pharmaceutical companies working on developing new gene therapies for these conditions.
Market Competition
Key players in the market include companies such as Voyager Therapeutics, Spark Therapeutics, Novartis AG, Bluebird bio, Inc., Biogen, Pfizer Inc., Rapa Therapeutics, BrainStorm Cell Therapeutics, Eli Lilly and Company, and UniQure Biopharma, along with healthcare providers and technology companies among other global players.
- In November 2022, a team of researchers at University College London (UCL) developed a novel gene therapy that offers promise in treating neurological and psychiatric disorders. The therapy targets overactive brain cells that are responsible for causing several brain diseases, including epilepsy, by reducing their excitability. By using DNA sequences that control gene expression, the therapy drives the production of molecules that prevent these overactive cells from firing, thereby curbing epileptic seizures. Notably, the technique selectively alters only overactive cells while sparing normally functioning cells.
- In preclinical studies, the new treatment demonstrated a higher efficacy than previous gene therapies or anti-seizure drugs tested in the same model. The team observed an approximately 80% reduction in spontaneous seizures in epileptic mice treated with the therapy. Furthermore, the researchers believe that this gene therapy has the potential to treat other disorders where some brain cells are overactive, such as Parkinson’s disease.
Key Companies Profiled
- Voyager Therapeutics
- Spark Therapeutics
- Novartis AG
- Bluebird Bio Inc.
- Biogen
- Pfizer Inc.
- Rapa Therapeutics
- BrainStorm Cell Therapeutics
- Eli Lily and Company
- UniQure Biopharma
Key Segments Profiled in the Gene Therapy in CNS Disorder Industry Survey
Indication:
- Alzheimer’s Disease
- Huntington’s Disease
- Parkinson’s Disease
- Batten Disease
Type:
- Ex Vivo
- In Vivo
End User:
- Hospitals
- Speciality Clinics
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
